| |
|
|
|
Akari Therapeutics Plc  
|
|
1.91 -0.04 (-0.02%) |
09-13 16:00 |
|
Open: |
2.25 |
Pre close: |
1.95 |
Target:
|
3.14
|
|
High: |
2.28 |
Low: |
1.85 |
Resistance:
|
2.69
3.35
|
|
Volume: |
2,300,496 |
Market Cap: |
39M |
Support:
|
1.61
1.34
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
1.92
 |
MACD |
MACD(12,26):
|
0.00  |
|
MA(20): |
1.88 |
Signal(12,26,9): |
-0.01 |
|
MA(100): |
2.26 |
Stochastic Oscillator |
%K(14,3):
|
40.59 |
|
MA(250): |
2.24 |
%D(3): |
38.46 |
|
Average Volume(K) |
3-Month: |
110180
|
52-Week |
High:
|
9.20 |
|
10-Days: |
182320 |
Low: |
1.56 |
|
RSI |
RSI(14):
|
49.74 |
Change(%): |
-9.9 |
|
Financials, Statistics and Valuation |
|
EPS |
-0.874 |
Return on Equity (ttm) |
-379.6 |
Shares Out. (M) |
20.41 |
|
EPS Est. Current Year |
-2.360 |
Return on Assets (ttm) |
-92.2 |
Shares Float (M) |
8.82 |
|
EPS Est. Next Year |
-3.110 |
PEG Ratio |
0.00 |
% Held by Insiders |
57.08 |
|
EPS Est. Next Quarter |
-0.660 |
Qtrly Rev. Growth |
0.0 |
% Held by Institutions |
5.55 |
|
Forward EPS |
-1.938 |
Gross Profit (p.s.) |
0.000 |
Shares Short (K) |
55 |
|
Book Value (p.s.) |
-0.080 |
EBITDA (p.s.) |
-0.804 |
P/E |
-2.19 |
|
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
-23.88 |
|
Profit Margin |
0.00 |
Operating Cash Flow
(M) |
-14.44 |
P/S |
0.00 |
|
Operating Margin |
0.00 |
Levered Free Cash Flow
(M) |
-11.27 |
P/CF |
-2.70 |
|
|
|
|
|
|
